TD Cowen analyst Phil Nadeau has maintained their bullish stance on KZR stock, giving a Buy rating today.
Phil Nadeau has given his Buy rating due to a combination of factors related to the promising results from Kezar Life Sciences’ recent clinical trial. The trial demonstrated that their drug, zetomipzomib, showed significant efficacy in treating autoimmune hepatitis (AIH), with 51% of patients achieving a complete response compared to 37% in the placebo group.
Additionally, the drug exhibited a favorable safety profile, which supports its advancement to pivotal development stages. Notably, in patients who were on steroids at the start of the trial, a substantial proportion achieved a complete response with a reduced steroid dosage, highlighting the drug’s potential to improve treatment outcomes. These positive outcomes contribute to the confidence in Kezar’s future prospects, justifying the Buy rating.
According to TipRanks, Nadeau is a 3-star analyst with an average return of 2.3% and a 42.15% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Biogen, and BioMarin Pharmaceutical.